(NASDAQ: BLTE) Belite Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.86%.
Belite Bio's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast BLTE's revenue for 2025 to be $1,591,327,450, with the lowest BLTE revenue forecast at $1,591,327,450, and the highest BLTE revenue forecast at $1,591,327,450. On average, 1 Wall Street analysts forecast BLTE's revenue for 2026 to be $795,663,725, with the lowest BLTE revenue forecast at $795,663,725, and the highest BLTE revenue forecast at $795,663,725.
In 2027, BLTE is forecast to generate $4,026,058,449 in revenue, with the lowest revenue forecast at $4,026,058,449 and the highest revenue forecast at $4,026,058,449.